Organon & Co. (OGN)

17,87 +0,08 (+0,45%) Alla chiusura: 04:00PM EDT

Organon & Co.

30 Hudson Street
Floor 33
Jersey City, NJ 07302
United States
551 430 6900
https://www.organon.com

Settore/i: Healthcare
Settore: Drug Manufacturers - General
Impiegati a tempo pieno: 10.000

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Kevin Ali	CEO & Director	3,96M	N/D	1960
Mr. Matthew M. Walsh	Executive VP & CFO	1,84M	N/D	1967
Ms. Susanne Gabriele Fiedler	Executive VP & Chief Commercial Officer	1,44M	N/D	1968
Mr. Joseph T. Morrissey Jr.	Executive VP and Head of Manufacturing & Supply	1,54M	N/D	1965
Ms. Rachel A. Stahler	Executive VP & Chief Information Officer	N/D	N/D	1976
Ms. Jennifer Halchak	Head of Investor Relations	N/D	N/D	N/D
Mr. Kirke Weaver	Executive VP, General Counsel & Corporate Secretary	N/D	N/D	1974
Ms. Susan O'Neal	Chief Ethics & Compliance Officer	N/D	N/D	N/D
Ms. Rebecca Lowell Edwards	Chief Communications Officer	N/D	N/D	N/D
Mr. Daniel Karp	Chief Business Development Officer	N/D	N/D	1978

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.

Governance aziendale

L'ISS Governance QualityScore di Organon & Co. al 1 aprile 2024 è 1. I criteri di valutazione fondamentali sono revisione: 4; Consiglio di Amministrazione: 1; diritti degli azionisti: 2; retribuzione: 2.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.